Healthy Subjects Clinical Trial
Official title:
A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled First-in-human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06648671 After Administration Of Single Ascending Doses To Fasted And Fed Healthy Subjects
Verified date | June 2015 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Belgium: Federal Agency for Medicinal Products and Health Products |
Study type | Interventional |
This is first in human (FIH), double-blind, sponsor open, placebo-control trial to examine the safety, tolerability, pharmacokinetics and pharmacodynamics following a single ascending doses of PF-06648671 in healthy subjects.
Status | Completed |
Enrollment | 18 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Healthy male and/or female subjects of non childbearing potential - BMI of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lbs) - Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study. Exclusion Criteria: - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drg allergies, but excluding untreated asymptomatic, seasonal allergies at the time of dosing); - Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer) - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Belgium | Pfizer Clinical Research Unit | Brussels |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with AEs and SAEs | Counts of participants who have TEAEs, defined as newly occuring or worsening after first dose. Relatedness to PF-06648671 will be assessed by the investigator (Yes/No). Participants with multiple occurences of an AE within a category will be counted once within the category | 0-6 weeks | Yes |
Primary | Supine vital sign measurement | Measurement of blood pressure and pulse rate | 0-6 weeks | Yes |
Primary | Electrocardiogram (ECG) | Measurement of standard 12-lead ECG, single or triplicate | 0-6 weeks | Yes |
Primary | Number of participants with lab test values of potential clinical importance | Pre-defined criteria were established for each lab test to identify potential clinical importance | 0-6 weeks | Yes |
Secondary | Maximum Observed Plasma Concentration (Cmax) | 0-72 hours post dose | No | |
Secondary | Area Under the Curve From Time Zeor to Last Quantifiable Concentration (AUClast) | 0-72 hours post dose | No | |
Secondary | Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) | 0-72 hours post dose | No | |
Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0-72 hours post dose | No | |
Secondary | Plasma Decay Half-life (t1/2) | 0-72 hours post dose | No | |
Secondary | Apparent Oral Clearance (CL/F) | 0-72 hours post dose | No | |
Secondary | Apparent Volume of Distribution (Vz/F) | 0-72 hours post dose | No | |
Secondary | Plasma Cmax ratio under fed vs fasted conditions | 0-72 hours post dose | No | |
Secondary | Plasma AUClast ratio under fed vs fasted condition | 0-72 hours post dose | No | |
Secondary | Plasma AUCinf ratio under fed vs fasted conditions | 0-72 hours post dose | No | |
Secondary | Plasma Abeta42 Maximum change from baseline | 0-72 hours post dose | No | |
Secondary | Plasma Abeta42, Area Under the Effect Curve from Time Zero to Last Quantifiable Concentration (AUEC) | 0-72 hours post dose | No | |
Secondary | Plasma Abeta42, Time to Reach Maximum Observed Effect (Tmax) | 0-72 hours post-dose | No | |
Secondary | Plasma Abeta40 Maximum change from baseline | 0-72 hours post dose | No | |
Secondary | Plasma Abeta40, Area Under the Effect Curve from Time Zero to Last Quantifiable Concentration (AUEC) | 0-72 hours post dose | No | |
Secondary | Plasma Abeta40, Time to Reach Maximum Observed Effect (Tmax) | 0-72 hours post-dose | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |